Peptides for Men Over 40: What Works, What to Rule Out, and Costs

Growth hormone is released in bursts, the largest during deep sleep. In healthy men sampled around the clock, daily secretion fell by roughly 14 percent per decade, through fewer bursts and faster clearance, and at any given age each extra unit of body mass index cut it by a further 6 percent or so (Journal of Clinical Endocrinology & Metabolism, 1991). The man who has gained weight since his thirties has lost growth hormone signaling on two counts, and the visceral fat that results is the most growth-hormone-responsive fat in the body. That is the logic behind GHRH analogs such as sermorelin, CJC-1295 and tesamorelin: they ask the pituitary for a larger pulse rather than supplying the hormone, the argument made in peptides vs HGH.

A pooled analysis of 149 healthy men aged 16 to 83 found deep slow-wave sleep falling from about 19 percent of the night in early adulthood to about 3 percent by ages 36 to 50, replaced by lighter sleep, with a parallel fall in growth hormone secretion; independent of age, growth hormone output tracked the amount of slow-wave sleep, and evening cortisol rose after 50 (JAMA, 2000). The sleep complaint and the recovery complaint are, physiologically, one complaint.

The Baltimore Longitudinal Study of Aging followed 890 men and found a steady, health-independent decline in total and free testosterone; about 20 percent of men over 60 had total testosterone in the hypogonadal range, rising with each decade (Journal of Clinical Endocrinology & Metabolism, 2001). The European Male Ageing Study of 3,369 men aged 40 to 79 found that only three symptoms, poor morning erections, low desire and erectile dysfunction, had a syndromic association with low testosterone; fatigue and low mood correlated but did not define the condition (New England Journal of Medicine, 2010). Most men over 40 do not have hypogonadism, and no peptide on this page treats it when they do.

Obstructive sleep apnea suppresses both hormones this page is about. In 225 men undergoing sleep studies, IGF-1 and total and free testosterone fell in proportion to apnea severity, independent of age and adiposity; in 43 men with severe apnea, three months of CPAP raised IGF-1 and total testosterone (Journal of Clinical Endocrinology & Metabolism, 1989). A man with untreated apnea who starts a GH-axis peptide is pushing against a brake that a mask releases.

Two further changes are mechanical. Tendon and ligament are poorly vascularized tissues that heal slowly at any age and more slowly with less growth hormone and IGF-1 signaling, which is why the shoulder from a decade ago is still there. And the fat gained after 40 is disproportionately visceral, inside the abdomen, metabolically active, and, unusually, responsive to growth hormone signaling in a way subcutaneous fat is not.

Two signals converging on one pulse. CJC-1295 is a long-acting GHRH analog; ipamorelin is a growth hormone secretagogue acting through the ghrelin receptor, described in its original characterization as the first selective one, with minimal effect on cortisol and prolactin at the doses studied (European Journal of Endocrinology, 1998). The human data: in healthy adults aged 21 to 61, single subcutaneous doses of CJC-1295 raised growth hormone two- to tenfold for six days or more and IGF-1 1.5- to threefold for nine to eleven days, with no serious adverse reactions, and growth hormone stayed pulsatile under continuous stimulation, with trough levels rising most (Journal of Clinical Endocrinology & Metabolism, 2006, two studies). Ipamorelin's human work is pharmacokinetic modeling in volunteers (Pharmaceutical Research, 1999) and a randomized proof-of-concept trial in post-operative ileus (International Journal of Colorectal Disease, 2014); there are no randomized human trials of ipamorelin for sleep, recovery or body composition. Who it suits: the man whose complaint is light sleep and slow recovery, with normal glucose, no cancer history and testosterone already checked. CJC-1295 / Ipamorelin is the usual starting point; what is CJC-1295 / Ipamorelin is the full reference.

The first 29 amino acids of GHRH, and the only peptide here that was itself the active ingredient of an FDA-approved drug. Much of its human evidence was gathered in older men. Twice-daily GHRH(1-29) restored growth hormone and IGF-1 in old men toward the levels of younger men (Journal of Clinical Endocrinology & Metabolism, 1992). Single nightly injections for six weeks in eleven healthy men aged 64 to 76 increased nocturnal growth hormone and two of six strength measures but did not change IGF-1, body composition, glucose or lipids; the authors concluded once-nightly dosing was less effective than multiple daily doses (Metabolism, 1997). A five-month placebo-controlled trial of a nightly GHRH analog in adults aged 55 to 71 reported raised nocturnal growth hormone and IGF-1, thicker skin in both sexes, and in men only increased lean mass, improved insulin sensitivity and better self-rated well-being and libido, with no change in sleep quality (Journal of Clinical Endocrinology & Metabolism, 1997). Who it suits: the man who wants the shortest-acting, longest-studied option in the class. Sermorelin is priced on its product page.

A stabilized GHRH(1-44) analog with the most specific evidence for the complaint men most often bring. In the pivotal trial, 412 people with HIV and abdominal fat accumulation, 86 percent men, received daily tesamorelin or placebo for 26 weeks: visceral fat fell 15.2 percent on tesamorelin and rose 5 percent on placebo, triglycerides fell, IGF-1 rose 81 percent, and glycemic measures did not differ (New England Journal of Medicine, 2007), a pattern confirmed in a pooled analysis of two phase 3 trials (Journal of Clinical Endocrinology & Metabolism, 2010). Closer to the man reading this, a 12-month randomized trial in 60 abdominally obese adults without HIV but with reduced growth hormone secretion reported a selective reduction in visceral fat with no effect on subcutaneous fat, improved triglycerides and C-reactive protein, and no worsening of glucose (Journal of Clinical Endocrinology & Metabolism, 2012). A six-month trial in HIV reported reductions in visceral and liver fat (JAMA, 2014), and a 20-week trial in healthy older adults reported favorable effects on cognition alongside a 117 percent rise in IGF-1 and a 7.4 percent fall in body fat (Archives of Neurology, 2012). Who it suits: the man whose measurement problem is his waist rather than the scale, with glucose checked first. Tesamorelin and Tesamorelin + Ipamorelin are both available.

Tesamorelin, CJC-1295, ipamorelin and BPC-157 in one vial: the GH-axis components above plus BPC-157 for the tendon or joint that limits training, as a single daily injection. Its evidence is the evidence of its parts; there is no trial of the blend. Who it suits: the man with both a recovery complaint and a specific soft-tissue problem, whose physician would otherwise have prescribed the pair. TITAN is priced on its product page.

ASCEND adds IGF-1 LR3 to the tesamorelin, CJC-1295 and ipamorelin core, and that changes the product's character. Everything else on this page asks the pituitary for more of its own hormone and leaves the body's feedback controls in place; IGF-1 LR3 is a modified IGF-1 that acts directly at the IGF-1 receptor and bypasses them. It carries the strongest cautions in the catalogue for that reason: any personal or family history of cancer, and hypoglycemia given cross-reactivity with the insulin receptor. There are no randomized human trials of IGF-1 LR3. It is a prescriber-led discussion for a man already on a GHRH pair, not a starting point. ASCEND and IGF-1 LR3 each have a full reference page.

The injury row. BPC-157 is a 15-amino-acid fragment of a protein in human gastric juice; animal and cell research describes it activating the VEGFR2 pathway that grows new blood vessels (Journal of Molecular Medicine, 2017), increasing growth hormone receptor expression in tendon fibroblasts (Molecules, 2014), and accelerating repair of transected and detached rat Achilles tendon (Journal of Orthopaedic Research, 2003 and 2006) and crushed rat muscle (Surgery Today, 2008). TB-500 is a fragment of thymosin beta-4, an actin-binding protein described as directing repair cells into injured tissue (Trends in Molecular Medicine, 2005; Nature, 2004); thymosin beta-4 itself has a randomized placebo-controlled safety study in healthy volunteers (Annals of the New York Academy of Sciences, 2010) and a phase 2 trial in severe dry eye (Cornea, 2015). For tendon and joint injury in humans there are no randomized controlled trials of either BPC-157 or TB-500. Who it suits: the man whose training is limited by a tendon, ligament or joint that has not settled with loading and time. BPC-157 + TB-500 is the combined vial; peptides for joint health goes deeper.

Bremelanotide, a melanocortin receptor agonist acting centrally on the desire pathway rather than on blood flow, which is the whole distinction from a PDE5 inhibitor. Its male record predates the approved product: placebo-controlled studies reported a significant erectile response to intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction, with onset in about 30 minutes and flushing and nausea the most common adverse events, and to subcutaneous PT-141 in men who had responded inadequately to sildenafil (International Journal of Impotence Research, 2004, two studies); low-dose intranasal PT-141 with sildenafil gave a larger response than sildenafil alone (Urology, 2005). The approved product, Vyleesi, was licensed for premenopausal women with hypoactive sexual desire disorder, and its trial program (Obstetrics & Gynecology, 2019; Journal of Women's Health, 2022) is the largest body of human safety information on the molecule: nausea in 40 percent, improving for most with the second dose, and a transient rise of about 6 mmHg systolic for a few hours after each dose. Who it suits: the man whose desire has dropped while the mechanics still work, with blood pressure controlled. PT-141 and PT-141 + Oxytocin are both available.

Not one of the four groups in the opening paragraph, but for the man whose problem is weight rather than fat distribution they have more evidence than everything else here combined. Semaglutide produced a mean 14.9 percent weight loss at 68 weeks against 2.4 percent on placebo in adults with overweight or obesity (New England Journal of Medicine, 2021), and in 17,604 adults with cardiovascular disease and overweight but no diabetes it reduced major cardiovascular events by 20 percent (New England Journal of Medicine, 2023). Tirzepatide produced 15 to 20.9 percent weight loss at 72 weeks depending on dose (New England Journal of Medicine, 2022), and in adults with obesity and moderate-to-severe obstructive sleep apnea it reduced the apnea-hypopnea index by 25 to 29 events per hour over a year (New England Journal of Medicine, 2024), the trial behind Zepbound's approval for that indication in December 2024. For the man whose fatigue, low testosterone and central fat trace back to apnea and obesity, this is often the more direct answer than anything in the GH-axis group. Best peptides for weight loss covers the choice between semaglutide and tirzepatide.

Sermorelin's older-adult trials reliably raised growth hormone, usually raised IGF-1 when dosed more than once a day, and produced small, inconsistent changes in strength, lean mass and skin thickness, with no change in sleep quality where it was measured. CJC-1295's human trials are pharmacokinetic: they establish what it does to hormone levels in healthy adults, not what that does to a man's body over a year. Tesamorelin is the exception, with randomized trials that measured visceral fat by CT scan and found it fell, in people with HIV and in obese adults with reduced growth hormone secretion. A 46-year-old with a normal pituitary and a softening waist is neither, and the approved product's label says plainly that it is not indicated for weight-loss management because its effect on weight is neutral. A man expecting the scale to move on tesamorelin has picked the wrong tool; a man expecting his waist to move has evidence on his side, from a population that was not quite him.

There are no randomized controlled trials of BPC-157 or TB-500 in humans for tendon, ligament or joint injury. The mechanistic story from animal and cell work is coherent and the prescribing experience is substantial; neither is a trial. The accurate framing is "described in preclinical research and used clinically," and a provider claiming proven human efficacy for either is overstating it.

PT-141's male trials were placebo-controlled and published, and they measured erectile response rather than desire. The approved product's label states it is not indicated for men and not indicated to enhance sexual performance. Prescribing to a man is off-label on a molecule with meaningful male data, which is a physician's decision and a common one across medicine.

• An effect size for sleep or recovery in a healthy man over 40 on any GH-axis peptide. That trial has not been run.
• A timeline in humans. What prescribers describe is clinical experience, not trial endpoints.
• Long-term safety of continuously raised IGF-1 in healthy adults. The approved tesamorelin label says the effects of prolonged IGF-1 elevation are unknown and directs monitoring, which is the honest position for the whole class.
• Efficacy for anything as an FDA-approved treatment. Compounded medications are prepared to a prescription; they are not approved as finished products.

Two cautions run through the whole growth-hormone-axis group: a personal history of cancer, and diabetes or impaired glucose tolerance, because growth hormone reduces insulin sensitivity. See peptide side effects.

A 503A pharmacy may compound with a bulk substance that has a USP or NF monograph, or that is a component of an FDA-approved drug, or that appears on the FDA's 503A bulks list. Nominated substances sit in interim categories while the FDA evaluates them; Category 2 is for substances flagged for significant safety concerns. The products here fall on different sides of that rule.

Both were placed in Category 2 in 2023. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective 22 April, noting that removal does not by itself place a substance on the bulks list. The FDA's safety-risks page, current as of 22 April 2026, lists BPC-157 and TB-500 (as "Thymosin Beta-4, Fragment") under "nominated but withdrawn," and the interim list updated 14 May 2026 has neither in any category; 503A Category 2 is down to six substances. On 23 July 2026 the Pharmacy Compounding Advisory Committee reviewed BPC-157 for ulcerative colitis and TB-500 for wound healing and voted 8 yes, 6 no, 1 abstain to recommend adding each to the 503A Bulks List, against the FDA staff position in both cases. A committee vote is a recommendation; listing requires rulemaking, and the FDA's final determination is pending. Today: neither is restricted, both are recommended for the positive list, both await final FDA action.

Both went through the committee earlier. On 29 October 2024 it considered ipamorelin, evaluated for growth hormone deficiency and post-operative ileus, and voted 0 yes, 12 no, 1 abstain against recommending it, members citing a lack of safety and efficacy data for those two uses. On 4 December 2024 it considered the CJC-1295 family, evaluated for growth hormone deficiency, and voted 0–13 against CJC-1295 free base and 1–12 against CJC-1295 acetate. Neither is in any category of the 14 May 2026 list; the safety-risks page lists both as "nominated but withdrawn" for 503A pharmacies, the FDA's stated concerns being immunogenicity for certain routes and peptide-related impurities, and for CJC-1295 reports of increased heart rate and a vasodilatory reaction. The committee evaluates a substance for the uses in its nomination against the approved drugs that already exist for them; a vote against is not a finding that the peptide is unsafe at prescribed doses, and it is not a ban. The FDA has not issued a final determination on either, and neither was on the July 2026 agenda.

Sermorelin acetate was the active ingredient of Geref, approved in 1990 as a diagnostic and in 1997 for growth hormone deficiency in children, and discontinued by its sponsor in 2008. In March 2013 the FDA published a formal determination that both Geref presentations were not withdrawn from sale for reasons of safety or effectiveness. It has never been in any category of the 503A interim list. There is no currently marketed FDA-approved sermorelin product; a compounded vial is not one.

An approved tesamorelin product exists: Egrifta, approved in 2010, with the current Egrifta WR formulation labeled in March 2025 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Its label carries three limitations of use, that long-term cardiovascular safety has not been established, that it is not indicated for weight-loss management, and that there are no data on antiretroviral compliance, and is contraindicated in active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. As the active ingredient of an approved product it was never nominated for the bulks list and appears in no category. Compounded tesamorelin is not Egrifta, and prescribing it to a man without HIV lipodystrophy is off-label.

Bremelanotide is the active ingredient of Vyleesi, approved on 21 June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compounded PT-141 therefore rests on the approved-component route rather than the bulks list, and it is in no category of the interim list. The compounded vial is not Vyleesi.

Both are FDA-approved active ingredients. The FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025, ending shortage-based compounding after wind-down periods. What remains is the ordinary 503A pathway: a state-licensed pharmacy may compound for an identified patient where the prescriber documents that a change from the commercial product produces a significant difference for that patient; the FDA's guidance, updated 1 April 2026, says adding vitamin B12 does not by itself take a product outside the "essentially a copy" definition where strengths are within 10 percent of commercial ones. On 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the separate 503B bulks list, a proposal concerning outsourcing facilities that does not change the 503A framework. Compounded semaglutide and tirzepatide are not Wegovy, Ozempic, Mounjaro or Zepbound.

Never nominated, never placed in any category, never reviewed by the committee; it appears on neither the 14 May 2026 list nor the safety-risks page. The FDA has published no position on it.

If you compete in tested sport, most of this page is prohibited at all times. The 2026 WADA Prohibited List, effective 1 January 2026, names CJC-1295, sermorelin and tesamorelin as examples of prohibited GHRH analogs, ipamorelin as a prohibited growth hormone secretagogue, IGF-1 and its analogs as prohibited growth factors, and thymosin beta-4 and its derivatives including TB-500; BPC-157 is named under S0, non-approved substances. Bremelanotide is not named. Tell your physician if you are tested.

What is reported early on a GH-axis peptide is mostly sleep: deeper, sometimes with vivid dreams, on evening dosing. Some men notice nothing in this window, which is normal. On PT-141 the first doses are where nausea and flushing are most likely; the approved product's label notes nausea improves for most with the second dose. On BPC-157 + TB-500 the early change described is background soreness settling rather than the injury itself changing.

Recovery between sessions is the change most often mentioned on the GH-axis products, and the one most easily confounded by the fact that the same man has usually also started sleeping and training more consistently. Tissue-level change on BPC-157 + TB-500, where it occurs, is described in this window, based on the animal timelines.

Visceral fat change on tesamorelin was measured in the trials at 26 weeks and 12 months. A tape measure at the navel, taken the same way each month, is the honest instrument; the scale is not, because the trials found weight neutral. Treatment is long-term: vials are sized for 28-day refills, one per fill, and the physician stays reachable for dose questions.